Log in
NASDAQ:ARCT

Arcturus Therapeutics Price Target, Predictions & Analyst Ratings

$79.50
+3.50 (+4.61 %)
(As of 11/30/2020 08:55 AM ET)
Add
Compare
Today's Range
$79.50
Now: $79.50
$81.20
50-Day Range
$34.61
MA: $53.56
$63.36
52-Week Range
$8.51
Now: $79.50
$80.76
Volume41 shs
Average Volume609,469 shs
Market Capitalization$1.95 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.85

Analyst Ratings

Arcturus Therapeutics (NASDAQ:ARCT) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
11 Wall Street analysts have issued ratings and price targets for Arcturus Therapeutics in the last 12 months. Their average twelve-month price target is $55.45, predicting that the stock has a possible downside of 30.25%. The high price target for ARCT is $78.00 and the low price target for ARCT is $19.00. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
ARCT Consensus Rating: BuyBuyBuyBuy
ARCT Consensus Rating Score: 2.912.912.893.00
ARCT Analyst Ratings: 0 Sell Rating(s)
1 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
ARCT Consensus Price Target: $55.45$57.64$55.22$29.50
ARCT Price Target Upside: 30.25% downside38.89% upside39.54% upside63.15% upside

Arcturus Therapeutics (NASDAQ:ARCT) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Arcturus Therapeutics (NASDAQ:ARCT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/11/2020B. RileyLower Price TargetBuy$82.00 ➝ $64.00High
11/10/2020Raymond JamesLower Price TargetOutperform$79.00 ➝ $73.00High
10/26/2020BarclaysInitiated CoverageOverweight$72.00Medium
10/6/2020CitigroupInitiated CoverageBuy ➝ Buy$65.00High
8/25/2020Piper SandlerInitiated CoverageOverweight$77.00Medium
8/11/2020Brookline Capital ManagementReiterated RatingBuyLow
8/11/2020HC WainwrightReiterated RatingBuy$78.00High
7/30/2020Roth CapitalInitiated CoverageBuy$77.00Medium
6/9/2020WBB SecuritiesDowngradeBuy ➝ Hold$31.00Low
3/18/2020Robert W. BairdReiterated RatingBuy$26.00High
3/5/2020LADENBURG THALM/SH SHBoost Price Target$22.00 ➝ $28.00High
2/6/2020GuggenheimInitiated CoverageBuy$19.00High
6/20/2019Chardan CapitalSet Price TargetBuy$18.00High
2/19/2019LaidlawInitiated CoverageBuyLow
(Data available from 11/30/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)
This page was last updated on 11/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.